PMV Pharmaceuticals Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Die Erträge von PMV Pharmaceuticals sind jährlich um durchschnittlich -24.2% zurückgegangen, während in der Branche Biotechs die Erträge jährlich um gewachsen sind und sich dabei auf 15.5% belaufen.

Wichtige Informationen

-24.2%

Wachstumsrate der Gewinne

54.0%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie	17.0%
Wachstumsrate der Einnahmen	n/a
Eigenkapitalrendite	-30.6%
Netto-Marge	n/a
Letzte Ertragsaktualisierung	31 Mar 2024

Jüngste Aktualisierungen vergangener Leistungen

Keine Aktualisierungen

Recent updates

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Apr 20

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Dec 22

We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business Growth

Sep 08

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

May 10

PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans

Jan 11

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Sep 22

PMV Pharmaceuticals GAAP EPS of -$0.38 beats by $0.04

Aug 09

PMV Pharma joins Merck to study lead candidate with Keytruda

Jul 18

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Jun 09

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

Feb 23

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Nov 05

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

Jul 23

Aufschlüsselung der Einnahmen und Ausgaben

Wie PMV Pharmaceuticals Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

NasdaqGS:PMVP Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
31 Mar 24	-65	23	53
31 Dec 23	-69	24	56
30 Sep 23	-73	25	58
30 Jun 23	-74	25	58
31 Mar 23	-74	25	55
31 Dec 22	-73	25	52
30 Sep 22	-72	25	49
30 Jun 22	-69	25	45
31 Mar 22	-65	24	41
31 Dec 21	-58	22	36
30 Sep 21	-50	20	31
30 Jun 21	-44	17	27
31 Mar 21	-39	13	25
31 Dec 20	-34	11	24
30 Sep 20	-31	8	23
30 Jun 20	-28	7	22
31 Mar 20	-27	6	22
31 Dec 19	-25	6	21

Qualität der Erträge: PMVP ist derzeit unrentabel.

Wachsende Gewinnspanne: PMVP ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: PMVP ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 24.2% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von PMVP verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: PMVP ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Biotechs (-14.4%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: PMVP hat eine negative Eigenkapitalrendite (-30.61%), da es derzeit unrentabel ist.

PMV Pharmaceuticals Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Insufficient new directors

PMV Pharmaceuticals, Inc., Annual General Meeting, Jun 06, 2024

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Price target decreased by 54% to US$5.67

PMV Pharmaceuticals, Inc. Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220c-Positive Solid Tumors

PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer

PMV Pharmaceuticals, Inc. Announces Workforce Reduction of Approximately 30%

New minor risk - Market cap size

PMV Pharmaceuticals, Inc. Announces Chief Financial Officer Changes

PMV Pharmaceuticals, Inc. Announces Chief Financial Officer Changes

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Price target decreased by 39% to US$13.20

New minor risk - Market cap size

PMV Pharmaceuticals, Inc. Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types with TP53 Y220C Mutation

New major risk - Share price stability

PMV Pharmaceuticals, Inc. to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business Growth

New minor risk - Share price stability

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans

Price target decreased to US$38.50

PMV Pharmaceuticals, Inc. Announces Board Changes

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

PMV Pharmaceuticals GAAP EPS of -$0.38 beats by $0.04

PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

PMV Pharma joins Merck to study lead candidate with Keytruda

PMV Pharmaceuticals, Inc.(NasdaqGS:PMVP) dropped from Russell 2000 Growth Index

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

PMV Pharmaceuticals, Inc. Announces Preliminary Results from the Ongoing Phase 1/2 PYNNACLE Study of PC14586 in Patients

Price target decreased to US$43.33

PMV Pharmaceuticals, Inc. to Present PC14586 Phase 1 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Price target decreased to US$49.00

PMV Pharmaceuticals, Inc., Annual General Meeting, Jun 02, 2022

Price target decreased to US$53.17

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth

Chief Medical Officer exercised options and sold US$103k worth of stock

Co-Founder notifies of intention to sell stock

Insider exercised options and sold US$88k worth of stock

COO & CFO exercised options and sold US$138k worth of stock

Co-Founder notifies of intention to sell stock

Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation

COO & CFO exercised options and sold US$137k worth of stock

PMV Pharmaceuticals, Inc.(NasdaqGS:PMVP) dropped from Russell 2500 Value Index

Co-Founder notifies of intention to sell stock

Key Executive exercised options and sold US$832k worth of stock

Co-Founder notifies of intention to sell stock

COO & CFO exercised options and sold US$137k worth of stock

Chief Medical Officer exercised options and sold US$120k worth of stock

PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Strong Position To Grow Its Business

PMV Pharmaceuticals, Inc. Appoints Guillermina Lozano to Scientific Advisory Board

New 90-day high: US$61.51

Do Institutions Own PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares?

PMV Pharmaceuticals, Inc. Doses First Patient in Phase 1/2 Study of PC14586, a First-In-Class Precision Oncology Therapy That Targets Mutant P53

PMV Pharmaceuticals reports Q3 results

Pmv Pharmaceuticals, Inc. Grants Fda Fast Track Designation of Pc14586 for the Treatment of Advanced Cancer Patients That Have Tumors with A P53 Y220c Mutation

PMV Pharmaceuticals, Inc. has completed an IPO in the amount of $211.77 million.

Aufschlüsselung der Einnahmen und Ausgaben

Gewinn- und Umsatzhistorie

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Eigenkapitalrendite

Kapitalrendite

Rendite auf das eingesetzte Kapital

Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren